NEW YORK, Dec. 17 (GenomeWeb) - Bionomics will acquire Neurofit, a French contract research organization, in a €1.25 million ($1.65 million) cash-and-stock transaction expected to close before March 1, the Adelaide, Australia-based company said today.
Bionomics will pay €1 million in cash and € 250,000 in shares for Strasbourg, France-based Neurofit. The company conducts preclinical testing of developmental therapeutics for CNS disorders using cellular and animal models, and lists Novartis, Serono, Boehringer-Ingelheim, and Biogen as clients.
The acquisition will enhace Bionomics' therapeutic development capacity for CNS disorders, Bionomics said.
Additionally, the acquisition includes intellectual property rights to an animal model of Parkinson's Disease, developed by Institute Pasteur, and other animal models.